4AP for Carpal Tunnel Syndrome (CTS)

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Compression Neuropathy, Carpal Tunnel Syndrome

In brief

The investigators have found recent promising data supporting the use of a currently FDA approved drug, 4-aminopyridine, in the treatment of nerve injury including compression neuropathy. The purpose of this research is determine whether 4-aminopyridine can treat carpal tunnel syndrome or delay the need for formal surgical release in patients with known carpal tunnel syndrome who would otherwise undergo surgery.

Key facts

Study ID

NCT06294821

Run by

John Elfar

People needed

160

Starts

2026-11-01

Expected to finish

2028-07-01

Last updated by the study team

2026-01-26

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with non-traumatic carpal tunnel syndrome without any other confounding diagnosis (e.g. cubital tunnel syndrome, cervical nerve compression)
• Standard of care EDX testing within 6 months of study enrollment
• Cognitive ability to report sensory and motor deficit during examination.
• Able to complete twice daily dosing of 4-AP for the entire 6 week treatment period.
• Adults subject aged 18-90
• Ability to give written informed consent.
• Capable of safely undergoing electrodiagnostic testing (EDX).
• Availability for all study visits.

You may not qualify if…

• Inability to complete twice daily dosing during 6 week treatment period.
• History of multiple sclerosis, stroke or any other diagnosed neurological disorder
• History of hypersensitivity to AMPYRA® or 4-aminopyridine
• Current use of aminopyridine medications, including other compounded 4-AP
• Suspected renal impairment based on the Choyke questionnaire.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.